Kingdon Capital Management’s Carisma Therapeutics CARM Stock Holding History

Kingdon Capital Management’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-65,584	Closed	-$3.41M	–	73
2021 Q1	$3.41M	Sell	65,584 -20,000	-23%	-$944K	0.35%	52
2020 Q4	$2.31M	Sell	85,584 -1,877	-2%	-$47.6K	0.25%	51
2020 Q3	$2.45M	Hold	87,461	–	–	0.28%	56
2020 Q2	$1.26M	Hold	87,461	–	–	0.11%	52
2020 Q1	$981K	Sell	87,461 -4,820	-5%	-$79K	0.18%	48
2019 Q4	$1.92M	Sell	92,281 -215,485	-70%	-$4.95M	0.29%	44
2019 Q3	$7.2M	Sell	307,766 -543	-0.2%	-$12.7K	0.85%	41
2019 Q2	$9.25M	Buy	308,309 +46,331	+18%	+$1.39M	0.91%	38
2019 Q1	$5.4M	Hold	261,978	–	–	0.72%	41
2018 Q4	$7.44M	Buy	261,978 +39,700	+18%	+$1.27M	1.12%	36
2018 Q3	$9.56M	Hold	222,278	–	–	0.67%	56
2018 Q2	$8.67M	Buy	222,278 +161,982	+269%	+$7.14M	0.6%	61
2018 Q1	$1.27M	Buy	+60,296	New	+$1.16M	0.1%	99

Other funds holding CARM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kingdon Capital Management's CARM Position: Q2 2021 in Review

Kingdon Capital Management sold out of Carisma Therapeutics (CARM) in Q2 2021, closing a stake of 65,584 shares — an estimated $3.41M sold.

Kingdon Capital Management first reported a position in CARM in Q1 2018 and held it in 13 quarters. The position peaked at $9.56M in Q3 2018. 105 funds tracked by Wall St. Rank hold CARM as of Q2 2021.

Kingdon Capital Management reported no remaining Carisma Therapeutics position as of Q2 2021 after selling out during the quarter.
Kingdon Capital Management sold 65,584 Carisma Therapeutics shares in Q2 2021, an estimated $3.41M.
Kingdon Capital Management first reported a position in Carisma Therapeutics in Q1 2018 and held it in 13 quarters.
Kingdon Capital Management's Carisma Therapeutics position peaked at $9.56M in Q3 2018.
105 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2021.

Based on Kingdon Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.